Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Income from Continuing Operations came in at 13200000.0 in Q2 2026, up 96.48% YoY from 6718273.15 in Q2 2025, and up 44.07% on a QoQ basis from 23600000.0 in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Income from Continuing Operations data on file, last reported at 13200000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 96.48% year-over-year to 13200000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 85200000.0 (up 91.73% YoY) and the FY2025 annual result came in at 986200000.0, down 263.24% from the prior year.
- Income from Continuing Operations improved to 13200000.0 in Q2 2026, from 23600000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 66400000.0 in Q2 2022 to a low of 562900000.0 in Q1 2025.
- A 5-year average of 71341176.47 and a median of 18500000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 1097.5% — and 2026, when it surged 96.48%.
- Tracing FTRE's Income from Continuing Operations over 5 years: stood at 13600000.0 in 2022, then slumped by 257.35% to 48600000.0 in 2023, then sank by 52.06% to 73900000.0 in 2024, then soared by 56.02% to 32500000.0 in 2025, then surged by 59.38% to 13200000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13200000.0 (Q2 2026), 23600000.0 (Q1 2026), and 32500000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | -13.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.20 Mn |
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -73.90 Mn |
| Sep 30, 2024 | -18.50 Mn |
| Jun 30, 2024 | -99.30 Mn |
| Mar 31, 2024 | -79.80 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -16.10 Mn |
| Jun 30, 2023 | 25.00 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | 66.40 Mn |